Markets
Stocks
Mutual Funds & ETF's
Sectors
Rates
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
NYSE MKT COMPOSITE
Peregrine Reports Upbeat Review Results
By:
MarketMinute.com Stock News
Peregrine Pharmaceuticals Inc. (
Nasdaq: PPHM
) reported upbeat results from an internal review of a Phase II trial of its second-line non-small cell lung cancer treatment bavituximab sending the stock price soaring 89 cents to $2.24.
Related Stocks:
PEREGRINE PHARMA
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here